Featured Publications
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease
JIANG Y, Zhou X, Wong H, Li O, Ip F, Chau V, Lau S, Wu W, Wong D, Seo H, Fu W, Lai N, Chen Y, Chen Y, Tong E, Mok V, Kwok T, Mok K, Shoai M, Lehallier B, Moran‐Losada P, O’Brien E, Porter T, Laws S, Hardy J, Wyss‐Coray T, Masters C, Fu A, Ip N, Initiative A. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.064428.Peer-Reviewed Original ResearchGenome-wide association studiesGenetic regulationAlzheimer's diseaseGenome-wide association study analysisGenetic variantsPathogenesis of Alzheimer's diseaseAD risk genesDisease-causing roleAPOE-e4 carriersAssociation studiesGenetic variationAmyloid-betaRisk genesMicroglial clearanceBrains of patientsBackground genetic factorsAD therapySevere neurodegenerationMicroglial dysfunctionAb accumulationMicroglial functionDecoy receptorGenetic factorsAPOE-e4IL1RL1
2022
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
Jiang Y, Zhou X, Wong H, Ouyang L, Ip F, Chau V, Lau S, Wu W, Wong D, Seo H, Fu W, Lai N, Chen Y, Chen Y, Tong E, Mok V, Kwok T, Mok K, Shoai M, Lehallier B, Losada P, O’Brien E, Porter T, Laws S, Hardy J, Wyss-Coray T, Masters C, Fu A, Ip N. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease. Nature Aging 2022, 2: 616-634. PMID: 37117777, PMCID: PMC10154240, DOI: 10.1038/s43587-022-00241-9.Peer-Reviewed Original ResearchConceptsAssociated with Alzheimer's diseaseGenetic variantsGenome-wide association analysisDisease-causing roleCRISPR-Cas9 genome editingEuropean-descent populationsAlzheimer's diseaseMouse transcriptomeDisease-causing factorsGenetic variationAmyloid-betaEnhancer elementsAssociation analysisDownregulated genesAD riskGenome editingMendelian randomization analysisLower AD riskDecoy receptorProtein levelsAPOE-e4Female individualsProteinVariantsModulation of microglial activation